Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

22-06-2023 | Non-Hodgkin Lymphoma | Congress News | News

EHA 2023

No radiotherapy required for patients with PMBCL in remission

Login to get access

MedNet.nl: The IELSG37 study provides robust evidence that radiotherapy can be omitted in patients with primary mediastinal B cell lymphoma (PMBCL) who have achieved a complete metabolic response (CMR) with dose-intensive immunochemotherapy.

Related topics

EHA 2023 rotated-square
Radiotherapy rotated-square
Hematologic Cancer rotated-square
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits